var data={"title":"Dantrolene: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dantrolene: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5976?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dantrolene-drug-information\" class=\"drug drug_general\">see &quot;Dantrolene: Drug information&quot;</a> and <a href=\"topic.htm?path=dantrolene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dantrolene: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708692\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene has a potential for hepatotoxicity; do not use in conditions other than those recommended. Symptomatic hepatitis (fatal and nonfatal) has been reported at various dose levels of the drug. The incidence reported in patients taking dosages of up to 400 mg/day is much lower than in those taking dosages of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in women, patients older than 35 years, and patients taking other medication(s). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving dantrolene. However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications. Use dantrolene only in conjunction with appropriate monitoring of hepatic function, including frequent determination of AST or ALT. If no observable benefit is derived from dantrolene after a total of 45 days, discontinue therapy. Prescribe the lowest possible effective dose for the individual patient.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156723\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dantrium;</li>\n      <li>Revonto;</li>\n      <li>Ryanodex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156724\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dantrium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057659\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Malignant Hyperthermia</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperthermia, Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Nonparalytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057651\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dantrolene-drug-information\" class=\"drug drug_general\">see &quot;Dantrolene: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spasticity:</b> Oral: <b>Note:</b> Titrate to desired effect; if no further benefit is observed at a higher dosage, decrease dose to previous lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children and Adolescents &ge;5 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;50 kg: Initial: 0.5 mg/kg/dose once daily for 7 days, increase to 0.5 mg/kg/dose 3 times daily for 7 days, increase to 1 mg/kg/dose 3 times daily for 7 days, and then increase to 2 mg/kg/dose 3 times daily; some patients may require 2 mg/kg/dose 4 times daily; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;50 kg: Initial: 25 mg once daily for 7 days, then increase to 25 mg 3 times daily for 7 days, then increase to 50 mg 3 times daily for 7 days, and then increase to 100 mg 3 times daily; some patients may require 100 mg 4 times daily; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Children and Adolescents: Initial: 0.5 mg/kg/dose twice daily (maximum dose: 25 mg/dose); titrate frequency then dose to desired effect by increasing frequency every 4 to 7 days up to 3 to 4 times daily; then increase dose by 0.5 mg/kg increments at weekly intervals to desired effect; maximum daily dose: 12 mg/kg/<b>day</b> or 400 mg/<b>day</b>, whichever is lower (Kliegman 2007; Krause 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignant hyperthermia:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preoperative prophylaxis: <b>Note:</b> Routine use not recommended provided that there is immediate availability of parenteral dantrolene and adequate perioperative patient management (eg, avoiding known trigger agents in susceptible patients):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 4 to 8 mg/kg/<b>day</b> in 3 to 4 divided doses for 1 to 2 days prior to surgery with the last dose administered approximately 3 to 4 hours before scheduled surgery</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 2.5 mg/kg/dose administered approximately 1.25 hours prior to surgery; infuse over at least 1 minute (Ryanodex) <b>or</b> 1 hour (Dantrium, Revonto) with additional doses as needed and individualized</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Crisis: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">MHAUS protocol recommendation (available at www.mhaus.org): 2.5 mg/kg; continuously repeat dose until symptoms subside or a cumulative dose of 10 mg/kg is reached (rarely, some patients may require up to 30 mg/kg for initial treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Initial minimum dose: 1 mg/kg; repeat dosing with a minimum of 1 mg/kg until symptoms subside or a cumulative dose of 10 mg/kg is reached</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>24-hour MH Hotline (for emergencies only):</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">United States: 1-800-644-9737</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Outside the US: 00-1-209-417-3722</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postcrisis follow-up:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">MHAUS protocol recommendation: 1 mg/kg every 4 to 6 hours (route not specified) <b>or</b> a continuous IV infusion of 0.25 mg/kg/hour for at least 24 hours; further doses may be indicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Oral: 4 to 8 mg/kg/day in 4 divided doses for 1 to 3 days; IV dantrolene may be used to prevent or attenuate recurrence of MH signs when oral therapy is not practical; individualize dosage beginning with 1 mg/kg or more as the clinical situation dictates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spasticity:</b> <b> Note:</b> Dose should be titrated and individualized for maximum effect; use the lowest dose compatible with optimal response. Some patients may not respond until a higher daily dosage is achieved; each dose level should be maintained for 7 days to determine patient response. If no further benefit observed with the higher dose level, then decrease dosage to previous dose level. Because of the potential for hepatotoxicity, stop therapy if benefits are not evident within 45 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: Oral: 25 mg once daily for 7 days, increase to 25 mg 3 times daily for 7 days, increase to 50 mg 3 times daily for 7 days, and then increase to 100 mg 3 times daily; some patients may require 100 mg 4 times daily; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignant hyperthermia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preoperative prophylaxis: <b>Note:</b> Dantrolene prophylaxis is not recommended for most MH-susceptible patients, provided nontriggering anesthetics are used and an adequate supply of dantrolene is available.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 4 to 8 mg/kg/<b>day</b> in 3 to 4 divided doses for 1 to 2 days prior to surgery with the last dose administered approximately 3 to 4 hours before scheduled surgery</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 2.5 mg/kg/dose administered approximately 1.25 hours prior to surgery; infuse over at least 1 minute (Ryanodex) <b>or</b> 1 hour (Dantrium, Revonto) with additional doses as needed and individualized</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Crisis: IV: 2.5 mg/kg (MHAUS recommendation, available at www.mhaus.org); continuously repeat dose until symptoms subside or a cumulative dose of 10 mg/kg is reached (rarely, some patients may require up to 30 mg/kg for initial treatment). <b>Note:</b> Manufacturer's labeling suggests an initial minimum dose of 1 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>24-hour MH Hotline (for emergencies only):</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">United States: 1-800-644-9737</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Outside the US: 00-1-209-417-3722</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postcrisis follow-up:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">MHAUS protocol suggestion: 1 mg/kg every 4 to 6 hours (route not specified) <b>or</b> a continuous IV infusion of 0.25 mg/kg/hour for at least 24 hours; further doses may be indicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's recommendation: Oral: 4 to 8 mg/kg/day in 4 divided doses for 1 to 3 days; IV dantrolene may be used to prevent or attenuate recurrence of MH signs when oral therapy is not practical; individualize dosage beginning with 1 mg/kg or more as the clinical situation dictates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; use of oral dantrolene in patients with active liver disease (hepatitis or cirrhosis) is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156704\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium: 25 mg, 50 mg, 100 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium: 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revonto: 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ryanodex: 250 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156689\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057662\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Contents of capsule may be mixed with juice or liquid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium, Revonto: Administer crisis doses by rapid IV injection; preferably in large-bore IV or central line; for intermittent infusion (prophylaxis doses) over 1 hour or continuous IV infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ryanodex: Administer crisis doses by rapid IV injection; follow-up doses should be administered over at least 1 minute. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10460046\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution: Protect from light. Use reconstituted solution within 6 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dantrium: Store unreconstituted vials and reconstituted solutions at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Revonto: Store unreconstituted vials and reconstituted solutions at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ryanodex: Store unreconstituted vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Store reconstituted solutions at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057661\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (Dantrium, Revonto, Ryanodex: FDA approved in all ages); prevention of malignant hyperthermia in susceptible individuals (preoperative/postoperative administration) (Dantrium, Revonto, Ryanodex: FDA approved in all ages) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of spasticity associated with upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis (FDA approved in ages &ge;5 years and adults); preoperative/postoperative prevention and attenuation of malignant hyperthermia in susceptible individuals (FDA approved in ages &ge;5 years and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Dantrolene prophylaxis is not routinely recommended for most malignant hyperthermia susceptible patients, provided there is immediate availability of parenteral dantrolene and adequate perioperative patient management (eg, avoiding known trigger agents [eg, anesthetics] in susceptible patients). Although dantrolene is FDA approved in all ages for malignant hyperthermia, it does not usually occur in patients &lt;12 months of age and has not been reported at &lt;4 months of age (Chamley, 2000; Larach, 2010; Silva, 1999). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156768\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dantrium may be confused with danazol, Daraprim</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revonto may be confused with Revatio</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156766\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block (intravenous), cardiac failure, flushing (intravenous), phlebitis, tachycardia, variable blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, choking sensation, confusion, depression, dizziness, drowsiness (may persist for 48 hours post dose), fatigue, feeling abnormal, headache, insomnia, malaise, myasthenia, nervousness, seizure, speech disturbance, voice disorder (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption (capsules), diaphoresis, eczematous rash, erythema (intravenous), hair disease (abnormal growth), pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, dysgeusia, dysphagia (use caution at meal time on day of administration as swallowing may be difficult), gastric irritation, gastrointestinal hemorrhage, nausea, sialorrhea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Crystalluria, difficulty in micturition, erectile dysfunction, hematuria, nocturia, urinary frequency, urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, aplastic anemia, leukopenia, lymphocytic lymphoma, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (intravenous; pain, erythema, swelling), local tissue necrosis (with extravasation due to high product pH)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, limb pain (intravenous), myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision (intravenous), diplopia, epiphora, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea (intravenous), pleural effusion (with pericarditis), pulmonary edema (rare), respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Decrease in forced vital capacity (intravenous), dyspnea (intravenous), hepatic disease, hepatotoxicity (oral), increased liver enzymes (oral), respiratory muscle failure (intravenous)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156710\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no contraindications listed within the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Active hepatic disease (eg, cirrhosis, hepatitis); when spasticity is used to maintain upright posture/balance in locomotion or to obtain/maintain increased function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156693\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Oral: Has potential for hepatotoxicity; symptomatic hepatitis (fatal and nonfatal) has been reported.</b> <b>Higher doses (ie, &ge;800 mg/day), even sporadic short courses, may increase the risk of severe hepatic injury although hepatic injury may occur at doses &lt;400 mg/day. Overt hepatitis has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients &gt;35 years, and in those taking concurrent medications. A higher incidence of fatal hepatic events have been reported in the elderly, although concurrent disease states and concurrent use of potentially hepatotoxic drugs may have contributed. </b>Idiosyncratic and hypersensitivity reactions (sometimes fatal) of the liver have also occurred. Monitor hepatic function at baseline and as clinically indicated during treatment. Discontinue therapy if symptoms compatible with hepatitis, accompanied with abnormal liver function tests or jaundice occur or benefits are not observed within 45 days when utilized for chronic spasticity. Hepatic function usually reverts to normal upon discontinuation; if reinstitution of therapy is necessary, patients should be hospitalized and the drug initiated in very small and gradual dose increases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Muscle weakness: Loss of grip strength, weakness in the legs, dyspnea, respiratory muscle weakness, dysphagia, and decreased inspiratory capacity has occurred with IV dantrolene. Patients should not ambulate without assistance until they have normal strength and balance. Monitor patients for the adequacy of ventilation and for difficulty swallowing/choking.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Oral therapy may cause a photosensitivity reaction; use with caution during exposure to sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pleural effusion: Pleural effusion with associated eosinophilia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use oral therapy with caution in patients with severely impaired cardiac function due to myocardial disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic disease: Use oral therapy with caution in patients with history of hepatic disease or dysfunction; use is contraindicated in patients with active hepatic disease (eg, cirrhosis, hepatitis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use oral therapy with caution in patients with impaired pulmonary function (particularly in obstructive pulmonary disease).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Alkaline solution; may cause tissue necrosis if extravasated (vesicant); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mannitol: Injection may contain mannitol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IV dantrolene is not the only therapeutic approach for management of malignant hyperthermia. Supportive measures, including discontinuing trigger agents (eg, anesthetic agents), administering oxygen, utilizing cooling methods, and monitoring blood gases, urinary output, urine color, and electrolytes, must also be utilized and individualized. Administer diuretics to prevent late kidney injury due to myoglobinuria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156754\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156698\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13203&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Dantrolene may enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine).  Management: This interaction has only been described with intravenous dantrolene administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the hepatotoxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacidipine: May enhance the adverse/toxic effect of Dantrolene.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: Dantrolene may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156700\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10460044\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Dantrolene crosses the human placenta. Cord blood concentrations are similar to those in the maternal plasma at term. and  dantrolene can be detected in the newborn serum at delivery. Adverse events were not observed in the newborn following maternal doses of 100 mg/day administered orally prior to delivery (Shime, 1988). Uterine atony has been reported following dantrolene injection after delivery; however, this may be due in part to the mannitol contained in the IV preparation (Shin, 1995; Weingarten, 1987). Prophylactic use of dantrolene is not routinely recommended in pregnant women susceptible to MH prior to obstetric surgery, if use is needed, close monitoring of the mother and newborn is recommended (Krause 2004; Norman 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057658\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spasticity: Motor performance should be monitored for therapeutic outcomes; nausea, vomiting, and liver function tests (baseline and at appropriate intervals thereafter) should be monitored for potential hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Malignant hyperthermia: Cardiac, respiratory, and blood pressure monitoring; during and postacute phase: Per MHAUS protocol, patient should be observed in an ICU for at least 24 hours since recrudescence may occur; monitor for arrhythmias; monitor vital signs (including core temperature), electrolytes, ABG, CK, end tidal CO<sub>2</sub> (EtCO<sub>2</sub>)/capnography, urine output, urine myoglobin </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156692\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts directly on skeletal muscle by interfering with release of calcium ion from the sarcoplasmic reticulum; prevents or reduces the increase in myoplasmic calcium ion concentration that activates the acute catabolic processes associated with malignant hyperthermia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156709\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 70% (Allen 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 36.4 &plusmn; 11.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; major metabolites are 5-hydroxy dantrolene and an acetylamino metabolite of dantrolene.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (at birth): ~20 hours (Shime 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 7 years: 10 hours (range: 8.1 to 14.8 hours) (Lerman 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 4 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IV: 1 minute post-dose (dantrolene); 24 hours post-dose (5-hydroxy dantrolene)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (45% to 50%); urine (25% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3946546\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">MHAUS (www.mhaus.org) provides educational and technical information to patients and healthcare providers. Triggers for the development of malignant hyperthermia in susceptible individuals include: All volatile inhalation anesthetics (desflurane, sevoflurane, isoflurane, halothane, enflurane, ether, methoxyflurane, and cyclopropane) and succinylcholine. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156708\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 5 mg/mL oral suspension may be made with dantrolene capsules, a citric acid solution, and either simple syrup or syrup BP (containing 0.15% w/v methylhydroxybenzoate). Add the contents of five 100 mg dantrolene capsules to a citric acid solution (150 mg citric acid powder in 10 mL water); mix while adding the chosen vehicle in incremental proportions to <b>almost</b> 100 mL. Transfer to a calibrated bottle and add quantity of vehicle sufficient to make 100 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Simple syrup suspension is stable for 2 days refrigerated; syrup BP suspension is stable for 30 days refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156712\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dantrium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $128.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $200.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dantrolene Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $96.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $155.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $195.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dantrium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $106.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Revonto Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ryanodex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $3,008.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038594\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anorex (KR);</li>\n      <li>Dantamacrin (BG, CH, DE);</li>\n      <li>Dantrium (AU, BB, BE, CY, DK, FR, GB, GR, IE, IL, IT, JP, LU, MT, NL, NZ, PT, QA, SI, TR, VN, ZA);</li>\n      <li>Dantrolen (AR, AT, BG, BR, CZ, RU);</li>\n      <li>Degison (TW);</li>\n      <li>Relaxo (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen GC, Cattran CB, Peterson RG, et al, &quot;Plasma Levels of Dantrolene Following Oral Administration in Malignant Hyperthermia-Susceptible Patients,&quot; <i>Anesthesiology</i>, 1988, 69(6):900-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/14661655/pubmed\" target=\"_blank\" id=\"14661655\">14661655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamley D, Pollock NA, Stowell KM, et al, &quot;Malignant Hyperthermia in Infancy and Identification of Novel RYR1 Mutation,&quot; <i>Br J Anaesth</i>, 2000, 84(4):500-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/10823104/pubmed\" target=\"_blank\" id=\"10823104\">10823104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dantrium (dantrolene sodium injection) [prescribing information]. Rochester, MI: JHP Pharmaceuticals, LLC; November 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delgado MR, Hirtz D, Aisen M, et al, &quot;Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2010, 74(4):336-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20101040/pubmed\" target=\"_blank\" id=\"20101040\">20101040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricker RM, Hoerauf KH, Drewe J, et al, &quot;Secretion of Dantrolene Into Breast Milk After Acute Therapy of a Suspected Malignant Hyperthermia Crisis During Cesarean Section,&quot; <i>Anesthesiology</i>, 1998, 89(4):1023-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/9778021/pubmed\" target=\"_blank\" id=\"9778021\">9778021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glahn KP, Ellis FR, Halsall PJ, et al, &quot;Recognizing and Managing a Malignant Hyperthermia Crisis: Guidelines From the European Malignant Hyperthermia Group,&quot; <i>Br J Anaesth</i>, 2010, 105(4):417-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20837722/pubmed\" target=\"_blank\" id=\"20837722\">20837722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krause T, Gerbershagen MU, Fiege M, et al, &quot;Dantrolene - A Review of Its Pharmacology, Therapeutic Use and New Developments,&quot; <i>Anaesthesia</i>, 2004, 59(4):364-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/15023108/pubmed\" target=\"_blank\" id=\"15023108\">15023108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larach MG, Gronert GA, Allen GC, et al, &quot;Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America From 1987 to 2006,&quot; <i>Anesth Analg</i>, 2010, 110(2):498-507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/20081135/pubmed\" target=\"_blank\" id=\"20081135\">20081135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerman J, McLeod ME, and Strong HA, &quot;Pharmacokinetics of Intravenous Dantrolene in Children,&quot; <i>Anesthesiology</i>, 1989, 70(4):625-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/2929999 /pubmed\" target=\"_blank\" id=\"2929999 \">2929999 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malignant Hyperthermia Association of the United States (MHAUS), &quot;Guidelines and 24-Hour Hotline.&quot; Available at http://www.mhaus.org/healthcare-professionals/#.T6rV3VI2cTY</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norman PF and Eichhorn JH, &quot;Management of Anesthetic Complications and Emergencies in the Obstetric Patient,&quot; <i>Obstet Gynecol Clin North Am</i>, 1995, 22(1):1-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/7784032/pubmed\" target=\"_blank\" id=\"7784032\">7784032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revonto (dantrolene sodium injection, powder, lyophilized, for solution) [prescribing information]. Greenville, NC: DSM Pharmaceuticals, Inc; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryanodex (dantrolene sodium for injectable suspension) [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shime J, Gare D, Andrews J, et al, &quot;Dantrolene in Pregnancy: Lack of Adverse Effects on the Fetus and Newborn Infant,&quot; <i>Am J Obstet Gynecol</i>, 1988, 159(4):831-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3177531 /pubmed\" target=\"_blank\" id=\"3177531 \">3177531 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shin YK, Kim YD, Collea JV, et al, &quot;Effect of Dantrolene Sodium on Contractility of Isolated Human Uterine Muscle,&quot; <i>Int J Obstet Anesth</i>, 1995, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/15637010/pubmed\" target=\"_blank\" id=\"15637010\">15637010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silva RR, Munoz DM, Alpert M, et al, &quot;Neuroleptic Malignant Syndrome in Children and Adolescents,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38(2):187-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/9951218/pubmed\" target=\"_blank\" id=\"9951218\">9951218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weingarten AE, Korsh JI, Neuman GG, et al, &quot;Postpartum Uterine Atony After Intravenous Dantrolene,&quot; <i>Anesth Analg</i>, 1987, 66(3):269-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dantrolene-pediatric-drug-information/abstract-text/3826671/pubmed\" target=\"_blank\" id=\"3826671\">3826671</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13203 Version 162.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708692\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156723\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156724\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057659\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057651\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156704\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F156689\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057662\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10460046\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057661\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156768\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156766\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156710\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156693\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F156754\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156698\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156700\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10460044\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057658\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156692\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F156709\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F3946546\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F156708\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F156712\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038594\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13203|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dantrolene-drug-information\" class=\"drug drug_general\">Dantrolene: Drug information</a></li><li><a href=\"topic.htm?path=dantrolene-patient-drug-information\" class=\"drug drug_patient\">Dantrolene: Patient drug information</a></li></ul></div></div>","javascript":null}